

Kamlesh Khunti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11671712/publications.pdf>

Version: 2024-02-01

351
papers

32,199
citations

7096

78
h-index

5255

165
g-index

373
all docs

373
docs citations

373
times ranked

36861
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. <i>Journal of Public Health</i> , 2023, 45, e65-e74.	1.8	26
2	COVID-19 and Diabetes. <i>Annual Review of Medicine</i> , 2022, 73, 129-147.	12.2	52
3	Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta-ethnography. <i>Diabetic Medicine</i> , 2022, 39, e14678.	2.3	10
4	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study. <i>Diabetic Medicine</i> , 2022, 39, e14697.	2.3	4
5	Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. <i>Journal of Public Health</i> , 2022, 44, 234-245.	1.8	60
6	Indirect effects of the COVID-19 pandemic on people with type 2 diabetes: time to urgently move into a recovery phase. <i>BMJ Quality and Safety</i> , 2022, 31, 483-485.	3.7	11
7	From the United Kingdom to Australia—Adapting a Web-Based Self-management Education Program to Support the Management of Type 2 Diabetes: Tutorial. <i>Journal of Medical Internet Research</i> , 2022, 24, e26339.	4.3	1
8	The impact of the COVID pandemic on primary care diabetes services in the UK: A cross-sectional national survey of views of health professionals delivering diabetes care. <i>Primary Care Diabetes</i> , 2022, 16, 257-263.	1.8	16
9	Open science communication: The first year of the UK's Independent Scientific Advisory Group for Emergencies. <i>Health Policy</i> , 2022, 126, 234-244.	3.0	12
10	Predictors of adverse outcome in the first and second waves of the COVID-19 pandemic: results from a UK centre. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210745.	1.8	1
11	The authors reply. <i>Kidney International</i> , 2022, 101, 420-421.	5.2	1
12	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. <i>Nature Communications</i> , 2022, 13, 624.	12.8	29
13	Association of Ethnicity and Socioeconomic Status With COVID-19 Hospitalization and Mortality in Those With and Without Chronic Kidney Disease. <i>Kidney International Reports</i> , 2022, 7, 334-338.	0.8	1
14	Association between household size and COVID-19: A UK Biobank observational study. <i>Journal of the Royal Society of Medicine</i> , 2022, 115, 138-144.	2.0	14
15	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2022, 13, 619-634.	2.5	17
16	Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1187-1196.	4.4	12
17	Healthcare workers' views on mandatory SARS-CoV-2 vaccination in the UK: A cross-sectional, mixed-methods analysis from the UK-REACH study. <i>EClinicalMedicine</i> , 2022, 46, 101346.	7.1	27
18	The effectiveness of a structured group education programme for people with established type 2 diabetes in a multi-ethnic population in primary care: A cluster randomised trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1549-1559.	2.6	5

#	ARTICLE	IF	CITATIONS
19	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. <i>Diabetes Care</i> , 2022, 45, 1132-1140.	8.6	4
20	Ethnic differences in the relationship between step cadence and physical function in older adults. <i>Journal of Sports Sciences</i> , 2022, 40, 1183-1190.	2.0	0
21	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. <i>Heart</i> , 2022, 108, 1200-1208.	2.9	10
22	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102484.	3.6	6
23	New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes. <i>Endocrine Practice</i> , 2022, 28, 811-821.	2.1	10
24	Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1469-1482.	4.4	0
25	Investigation of a UK biobank cohort reveals causal associations of self-reported walking pace with telomere length. <i>Communications Biology</i> , 2022, 5, 381.	4.4	17
26	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1734-1740.	4.4	0
27	Efficacy of COVID-19 vaccines by race and ethnicity. <i>Public Health</i> , 2022, , .	2.9	6
28	Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 561-570.	11.4	32
29	The impact of the COVID-19 pandemic on glycaemic control in people with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1850-1860.	4.4	24
30	Strategies to record and use ethnicity information in routine health data. <i>Nature Medicine</i> , 2022, 28, 1338-1342.	30.7	31
31	Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2138-2147.	4.4	4
32	Ethnicity and prognosis following a cardiovascular event in people with and without type 2 diabetes: Observational analysis in over 5 million subjects in England. <i>Diabetes Research and Clinical Practice</i> , 2022, 189, 109967.	2.8	2
33	Predictors and determinants of albuminuria in people with prediabetes and diabetes based on smoking status: A cross-sectional study using the UK Biobank data. <i>EClinicalMedicine</i> , 2022, 51, 101544.	7.1	4
34	Mortality risk comparing walking pace to handgrip strength and a healthy lifestyle: A UK Biobank study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 704-712.	1.8	25
35	Cardiovascular events and mortality in people with and without type 2 diabetes: An observational study in a contemporary multiethnic population. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1175-1182.	2.4	18
36	Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 218-227.	4.4	10

#	ARTICLE	IF	CITATIONS
37	Development, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal tool. <i>Annals of Epidemiology</i> , 2021, 55, 57-63.e15.	1.9	3
38	Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: An observational analysis of the ADDITION-Europe trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 730-741.	4.4	6
39	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	3.9	110
40	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108616.	2.8	2
41	The need for improved collection and coding of ethnicity in health research. <i>Journal of Public Health</i> , 2021, 43, e270-e272.	1.8	30
42	Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. <i>Diabetic Medicine</i> , 2021, 38, e14469.	2.3	17
43	Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. <i>Primary Care Diabetes</i> , 2021, 15, 218-226.	1.8	5
44	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. <i>Primary Care Diabetes</i> , 2021, 15, 59-68.	1.8	9
45	Comparing 24 h physical activity profiles: Office workers, women with a history of gestational diabetes and people with chronic disease condition(s). <i>Journal of Sports Sciences</i> , 2021, 39, 219-226.	2.0	8
46	Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. <i>Diabetes Care</i> , 2021, 44, 915-924.	8.6	16
47	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1255-1268.	3.6	23
48	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 289-292.	11.9	33
49	Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank. <i>International Journal of Obesity</i> , 2021, 45, 1155-1159.	3.4	43
50	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. <i>BMJ, The</i> , 2021, 372, n693.	6.0	494
51	Temporal trends in comorbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1150-1161.	4.4	10
52	COVID-19 and the new variant strain in England – What are the implications for those from ethnic minority groups?. <i>EClinicalMedicine</i> , 2021, 33, 100805.	7.1	5
53	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. <i>Obesity</i> , 2021, 29, 1223-1230.	3.0	34
54	Assessing risk for healthcare workers during the covid-19 pandemic. <i>BMJ, The</i> , 2021, 372, n602.	6.0	35

#	ARTICLE	IF	CITATIONS
55	Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real-world evidence from primary care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1518-1531.	4.4	10
56	Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation. <i>European Journal of Public Health</i> , 2021, 31, 630-634.	0.3	20
57	Ethnicity, household composition and COVID-19 mortality: a national linked data study. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 182-211.	2.0	69
58	Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol. <i>BMJ Open</i> , 2021, 11, e045286.	1.9	0
59	Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion. <i>Diabetes Therapy</i> , 2021, 12, 1491-1501.	2.5	5
60	Gait Speed as a Predictor for Diabetes Incidence in People with or at Risk of Knee Osteoarthritis: A Longitudinal Analysis from the Osteoarthritis Initiative. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4414.	2.6	6
61	Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. <i>Journal of Epidemiology and Community Health</i> , 2021, 75, 970-974.	3.7	100
62	Long COVID – metabolic risk factors and novel therapeutic management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 379-380.	9.6	38
63	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LiFestyle Cohort Twente (DIALECT). <i>Diabetes Care</i> , 2021, 44, 1419-1425.	8.6	11
64	Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic. <i>Diabetes Care</i> , 2021, 44, e133-e135.	8.6	18
65	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	2.2	18
66	Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. <i>Lancet, The</i> , 2021, 397, 1711-1724.	13.7	332
67	A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. <i>Diabetologia</i> , 2021, 64, 1717-1724.	6.3	18
68	Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 293-303.	11.4	140
69	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. <i>BMC Medicine</i> , 2021, 19, 130.	5.5	14
70	Cohort profile: National Diabetes Audit for England and Wales. <i>Diabetic Medicine</i> , 2021, 38, e14616.	2.3	21
71	United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): a retrospective cohort study using linked routinely collected data, study protocol. <i>BMJ Open</i> , 2021, 11, e046392.	1.9	9
72	Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. <i>European Journal of Epidemiology</i> , 2021, 36, 605-617.	5.7	66

#	ARTICLE	IF	CITATIONS
73	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. <i>Primary Care Diabetes</i> , 2021, 15, 1075-1079.	1.8	2
74	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021, 20, 159.	6.8	15
75	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. <i>BMJ Open</i> , 2021, 11, e051237.	1.9	16
76	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 717.	2.9	19
77	Clustering of comorbidities. <i>Future Healthcare Journal</i> , 2021, 8, e224-e229.	1.4	17
78	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 708372.	3.5	7
79	Ethnic, social and multimorbidity disparities in therapeutic inertia: A UK primary care observational study in patients newly diagnosed with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2437-2445.	4.4	7
80	Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100180.	5.6	116
81	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021, 52, 2494-2501.	2.0	10
82	Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2207-2214.	4.4	22
83	The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings. <i>BMJ Open</i> , 2021, 11, e050647.	1.9	26
84	EXTending availability of self-management structured Education programmes for people with type 2 Diabetes in low-to-middle income countries (EXTEND) – a feasibility study in Mozambique and Malawi. <i>BMJ Open</i> , 2021, 11, e047425.	1.9	3
85	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K.. <i>BMC Infectious Diseases</i> , 2021, 21, 908.	2.9	41
86	Normative wrist-worn accelerometer values for self-paced walking and running: a walk in the park. <i>Journal of Sports Sciences</i> , 2021, , 1-8.	2.0	4
87	Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 649-651.	11.4	17
88	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 108974.	2.8	3
89	Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 671-680.	11.4	45
90	Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 997-1007.	2.4	18

#	ARTICLE	IF	CITATIONS
91	Ethnic-minority groups in England and Wales—factors associated with the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking census and death records. <i>International Journal of Epidemiology</i> , 2021, 49, 1951-1962.	1.9	41
92	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, e32-e34.	8.6	12
93	Focused action is required to protect ethnic minority populations from COVID-19 post-lockdown. <i>British Journal of General Practice</i> , 2021, 71, 37-40.	1.4	8
94	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , 2021, 44, 2645-2655.	8.6	164
95	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108077.	2.3	3
96	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	11.4	155
97	Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. <i>Diabetes Care</i> , 2021, 44, 2790-2811.	8.6	41
98	SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study. <i>PLoS Medicine</i> , 2021, 18, e1003823.	8.4	48
99	Life expectancy by ethnic group in England. <i>BMJ</i> , 2021, 375, e068537.	6.0	3
100	Covid-19 and ethnicity: we must seek to understand the drivers of higher transmission. <i>BMJ</i> , 2021, 375, n2709.	6.0	10
101	The impact of COVID-19 on primary care: Insights from the National Health Service (NHS) and future recommendations. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 4345.	0.9	13
102	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-190.	2.8	7
103	Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action. <i>Trials</i> , 2021, 22, 880.	1.6	65
104	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
105	Early Outcomes From the English National Health Service Diabetes Prevention Programme. <i>Diabetes Care</i> , 2020, 43, 152-160.	8.6	116
106	Walking pace improves all-cause and cardiovascular mortality risk prediction: A UK Biobank prognostic study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1036-1044.	1.8	29
107	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.	4.4	20
108	Predictors of the Acute Postprandial Response to Breaking Up Prolonged Sitting. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 1385-1393.	0.4	13

#	ARTICLE	IF	CITATIONS
109	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 27-35.	11.4	215
110	The importance of the initial period of basal insulin titration in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 722-733.	4.4	24
111	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	5.2	692
112	Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. <i>BMJ, The</i> , 2020, 371, m3731.	6.0	471
113	Editorial: Studies in young adults with type 2 diabetes to inform evidence-based guidelines specifically for early-onset type 2 diabetes are urgently required. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1905-1906.	3.6	1
114	Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1725-1733.	3.6	7
115	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. <i>Clinical Diabetes</i> , 2020, 38, 371-381.	2.2	49
116	Temporal Trend in Young-Onset Type 2 Diabetes's Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. <i>Diabetes Care</i> , 2020, 43, 2208-2216.	8.6	24
117	Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study. <i>EClinicalMedicine</i> , 2020, 25, 100466.	7.1	129
118	The language of ethnicity. <i>BMJ, The</i> , 2020, 371, m4493.	6.0	30
119	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. <i>Lancet, The</i> , 2020, 396, 1705-1707.	13.7	22
120	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 172, 541.	3.9	53
121	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. <i>Pharmaceuticals</i> , 2020, 13, 427.	3.8	14
122	COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2241-2243.	3.6	5
123	Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2020, 29-30, 100630.	7.1	454
124	Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2417-2426.	4.4	13
125	Missed Opportunities for Timely Recognition of Chronic Limb Threatening Ischaemia in Patients Undergoing a Major Amputation: A Population Based Cohort Study Using the UK's Clinical Practice Research Datalink. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 60, 703-710.	1.5	13
126	Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. <i>Diabetologia</i> , 2020, 63, 2129-2139.	6.3	15

#	ARTICLE	IF	CITATIONS
127	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	4.4	33
128	Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 823-833.	11.4	677
129	Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 813-822.	11.4	733
130	Who should be prioritised for COVID-19 vaccines?. <i>Lancet</i> , 2020, 396, 1732-1733.	13.7	36
131	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 810-811.	11.4	4
132	Early lessons from a second COVID-19 lockdown in Leicester, UK. <i>Lancet</i> , 2020, 396, e4-e5.	13.7	24
133	Effects of an Electronic Software Prompt With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1893-1901.	8.6	2
134	Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 20, 100225.	1.4	8
135	Cardiovascular outcome trials of glucose-lowering therapies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 237-249.	1.4	5
136	New-Onset Diabetes in Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 789-790.	27.0	624
137	Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108266.	2.8	62
138	The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. <i>EClinicalMedicine</i> , 2020, 23, 100404.	7.1	442
139	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108250.	2.8	4
140	Prevalence of comorbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1915-1924.	4.4	320
141	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	3.6	22
142	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	8.6	147
143	COVID-19 and ethnicity: who will research results apply to?. <i>Lancet</i> , 2020, 395, 1955-1957.	13.7	66
144	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 606-615.	11.4	67

#	ARTICLE	IF	CITATIONS
145	A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1187-1196.	4.4	13
146	COVID-19 and ethnicity: A novel pathophysiological role for inflammation. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1043-1051.	3.6	48
147	Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 965-967.	3.6	390
148	Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1035-1046.	4.4	46
149	Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 828-837.	4.4	1
150	Evaluation of the Diabetes Screening Component of a National Cardiovascular Risk Assessment Programme in England: a Retrospective Cohort Study. <i>Scientific Reports</i> , 2020, 10, 1231.	3.3	14
151	Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00107.	2.4	8
152	Ethnicity and COVID-19: an urgent public health research priority. <i>Lancet</i> , The, 2020, 395, 1421-1422.	13.7	388
153	The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 21-34.	4.4	16
154	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 546-550.	11.4	680
155	Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (<sc>SARS-CoV</sc> or <sc>COVID</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1942-1945.	4.4	9
156	Is ethnicity linked to incidence or outcomes of covid-19?. <i>BMJ</i> , The, 2020, 369, m1548.	6.0	408
157	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. <i>Diabetes Therapy</i> , 2020, 11, 33-48.	2.5	17
158	Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001061.	2.8	50
159	Introduction: Real-World Evidence in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 29-32.	2.5	1
160	Metformin for Preventing Type 2 Diabetes Mellitus in Women with a Previous Diagnosis of Gestational Diabetes: A Narrative Review. <i>Seminars in Reproductive Medicine</i> , 2020, 38, 366-376.	1.1	2
161	Validating the QCOVID risk prediction algorithm for risk of mortality from COVID-19 in the adult population in Wales, UK.. <i>International Journal of Population Data Science</i> , 2020, 5, 1697.	0.1	12
162	Relevance of physical function in the association of red and processed meat intake with all-cause, cardiovascular, and cancer mortality. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1308-1315.	2.6	11

#	ARTICLE	IF	CITATIONS
163	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2474-2485.	4.4	36
164	The right place for Sulphonylureas today: Part of "Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus". <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107836.	2.8	23
165	Comparative Relevance of Physical Fitness and Adiposity on Life Expectancy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 985-994.	3.0	42
166	Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881984469.	3.2	100
167	Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 537-547.	1.8	12
168	Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1132-1135.	8.6	16
169	Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12-month prospective observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1585-1595.	4.4	19
170	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.	2.8	63
171	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019, 35, 644-652.	1.7	1
172	Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000627.	2.8	14
173	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 385-396.	11.4	298
174	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1429-1436.	4.4	28
175	Effects of blood pressure and lipid lowering on cognition. <i>Neurology</i> , 2019, 92, e1435-e1446.	1.1	54
176	Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. <i>Diabetes Care</i> , 2019, 42, 349-351.	8.6	29
177	Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1373-1380.	4.4	11
178	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	2.5	15
179	Individualised targets for insulin initiation in type 2 diabetes mellitus—the influence of physician and practice: a cross-sectional study in eight European countries. <i>BMJ Open</i> , 2019, 9, e032040.	1.9	3
180	Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. <i>BMJ Open</i> , 2019, 9, e027773.	1.9	22

#	ARTICLE	IF	CITATIONS
181	Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 925-937.	11.4	39
182	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. <i>JAMA Network Open</i> , 2019, 2, e1916447.	5.9	4
183	Should sodium-glucose cotransporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 207-209.	4.4	4
184	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
185	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. <i>Canadian Journal of Diabetes</i> , 2019, 43, 384-391.	0.8	11
186	Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 844-853.	4.4	15
187	Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 98-107.	5.0	12
188	Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. <i>Liver International</i> , 2019, 39, 557-567.	3.9	62
189	Intensive versus standard multifactorial cardiovascular risk factor control in screen-detected type 2 diabetes: 5-year and longer-term modelled outcomes of the ADDITION-Leicester study. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3111.	4.0	11
190	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2018, 12, 265-283.	1.8	62
191	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq1 1 0.784314 r6BT /Overl	1.6	6
192	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 821-832.	11.4	83
193	Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. <i>Diabetes Research and Clinical Practice</i> , 2018, 138, 35-43.	2.8	19
194	Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1337-1341.	4.4	69
195	What have we learnt from "real world" data, observational studies and meta-analyses. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 47-58.	4.4	35
196	Sedentary Time and MRI-Derived Measures of Adiposity in Active Versus Inactive Individuals. <i>Obesity</i> , 2018, 26, 29-36.	3.0	17
197	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. <i>Canadian Journal of Cardiology</i> , 2018, 34, 38-44.	1.7	13
198	Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation. <i>Journal of Sports Sciences</i> , 2018, 36, 1586-1593.	2.0	20

#	ARTICLE	IF	CITATIONS
199	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 137-148.	2.8	114
200	Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. <i>Diabetologia</i> , 2018, 61, 1592-1602.	6.3	26
201	Screening for Diabetes and Prediabetes. <i>Endocrinology</i> , 2018, , 1-33.	0.1	1
202	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2628-2639.	2.8	370
203	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018, 131, 813-819.e5.	1.5	17
204	The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 392-399.	2.8	13
205	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2 inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1983-1987.	4.4	65
206	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 103-112.	4.4	65
207	Associations Between Sedentary Behaviors and Cognitive Function: Cross-Sectional and Prospective Findings From the UK Biobank. <i>American Journal of Epidemiology</i> , 2018, 187, 441-454.	3.4	64
208	Identification of barriers to insulin therapy and approaches to overcoming them. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 488-496.	4.4	167
209	Clinical inertia versus overtreatment in glycaemic management. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 266-268.	11.4	26
210	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 763-765.	4.4	0
211	Diabetes structured self-management education programmes: a narrative review and current innovations. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 130-142.	11.4	233
212	Therapeutic inertia amongst general practitioners with interest in diabetes. <i>Primary Care Diabetes</i> , 2018, 12, 87-91.	1.8	14
213	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 427-437.	4.4	247
214	Structured education programme for women with polycystic ovary syndrome: a randomised controlled trial. <i>Endocrine Connections</i> , 2018, 7, 26-35.	1.9	15
215	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 13-24.	2.2	4
216	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10%256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.	4.4	38

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. <i>BMJ Open</i> , 2018, 8, e023206.	1.9	4
218	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.	6.8	149
219	Clinical management of type 2 diabetes in south Asia. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 979-991.	11.4	49
220	Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 992-1002.	11.4	43
221	Epidemiology and determinants of type 2 diabetes in south Asia. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 966-978.	11.4	171
222	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. <i>Advances in Therapy</i> , 2018, 35, 1763-1774.	2.9	424
223	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 76-84.	2.8	12
224	Screening for Diabetes and Prediabetes. <i>Endocrinology</i> , 2018, , 369-400.	0.1	2
225	Glucose dysregulation phenotypes – time to improve outcomes. <i>Nature Reviews Endocrinology</i> , 2018, 14, 632-633.	9.6	6
226	SGLT-2 Inhibitors and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2497-2506.	2.8	113
227	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6-10. <i>Diabetes Care</i> , 2018, 41, e106-e108.	8.6	8
228	Polycystic ovary syndrome: An underestimated problem in primary care. <i>International Journal of Clinical Practice</i> , 2018, 72, e13081.	1.7	1
229	Patterns of Multimorbidity in Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. <i>Mayo Clinic Proceedings</i> , 2018, 93, 857-866.	3.0	105
230	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.	5.5	36
231	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. <i>Primary Care Diabetes</i> , 2018, 12, 383-392.	1.8	10
232	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2169-2178.	4.4	40
233	Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2096-2104.	8.6	40
234	Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 985-997.	4.4	23

#	ARTICLE	IF	CITATIONS
235	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
236	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technology Assessment, 2018, 22, 1-160.	2.8	39
237	The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e152.	1.0	1
238	Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification. Diabetes Research and Clinical Practice, 2017, 123, 209-217.	2.8	7
239	Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes. BMJ Open, 2017, 7, e014267.	1.9	37
240	Reducing sedentary time in adults at risk of type 2 diabetes: process evaluation of the STAND (Sedentary Time ANd Diabetes) RCT. BMC Public Health, 2017, 17, 80.	2.9	9
241	Clinical inertia—Time to reappraise the terminology?. Primary Care Diabetes, 2017, 11, 105-106.	1.8	79
242	Comparison of body mass index at diagnosis of diabetes in a multi-ethnic population: a case-control study with matched non-diabetic controls. Diabetes, Obesity and Metabolism, 2017, 19, 1014-1023.	4.4	45
243	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	4.4	100
244	Type 2 diabetes. Lancet, The, 2017, 389, 2239-2251.	13.7	1,691
245	Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections, 2017, 6, 323-330.	1.9	34
246	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017, 136, 249-259.	1.6	672
247	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open, 2017, 7, e013851.	1.9	21
248	Fitness Moderates Glycemic Responses to Sitting and Light Activity Breaks. Medicine and Science in Sports and Exercise, 2017, 49, 2216-2222.	0.4	33
249	Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese high-risk adults: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1732-1739.	4.4	24
250	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	2.8	53
251	Risk factors and outcome differences in hypoglycaemia-related hospital admissions: a case-control study in England. Diabetes, Obesity and Metabolism, 2017, 19, 1371-1378.	4.4	14
252	Barriers and Facilitators to Healthy Lifestyle Changes in Minority Ethnic Populations in the UK: a Narrative Review. Journal of Racial and Ethnic Health Disparities, 2017, 4, 1107-1119.	3.2	47

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 524-536.	4.4	305
254	Associations of Physical Activity Intensities with Markers of Insulin Sensitivity. <i>Medicine and Science in Sports and Exercise</i> , 2017, 49, 2451-2458.	0.4	14
255	Let's Prevent Diabetes: from idea to implementation. <i>Practical Diabetes</i> , 2017, 34, 55-57.	0.3	2
256	Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2017, 40, 1588-1596.	8.6	143
257	What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries. <i>BMJ Open</i> , 2017, 7, e016180.	1.9	28
258	Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. <i>Primary Care Diabetes</i> , 2017, 11, 414-420.	1.8	21
259	Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. <i>Acta Diabetologica</i> , 2017, 54, 209-214.	2.5	38
260	Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 329-335.	4.4	104
261	Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 108-117.	4.4	32
262	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. <i>Primary Care Diabetes</i> , 2017, 11, 3-12.	1.8	170
263	Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study. <i>European Heart Journal</i> , 2017, 38, 3232-3240.	2.2	168
264	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1569-1576.	2.0	4
265	Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. <i>Medicine and Science in Sports and Exercise</i> , 2017, 49, 1120-1125.	0.4	13
266	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-290.	1.0	12
267	Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-316.	1.0	11
268	Intensity Thresholds on Raw Acceleration Data: Euclidean Norm Minus One (ENMO) and Mean Amplitude Deviation (MAD) Approaches. <i>PLoS ONE</i> , 2016, 11, e0164045.	2.5	96
269	Sedentary Sphere. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 748-754.	0.4	55
270	Accuracy of Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 1085-1090.	0.4	80

#	ARTICLE	IF	CITATIONS
271	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	27.0	526
272	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	27.0	641
273	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	27.0	299
274	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. <i>Annals of Internal Medicine</i> , 2016, 164, 102.	3.9	70
275	New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 557-559.	11.4	7
276	Optimizing management of glycaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 397-411.	4.7	10
277	A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. <i>Preventive Medicine</i> , 2016, 84, 48-56.	3.4	83
278	Type 2 diabetes: lifetime risk of advancing from prediabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 5-6.	11.4	2
279	Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. <i>Journal of Public Health</i> , 2016, 38, 493-501.	1.8	23
280	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. <i>Diabetes Care</i> , 2016, 39, 130-138.	8.6	229
281	Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. <i>Journal of Diabetes</i> , 2016, 8, 354-362.	1.8	14
282	Engagement, Retention, and Progression to Type 2 Diabetes: A Retrospective Analysis of the Cluster-Randomised "Let's Prevent Diabetes" Trial. <i>PLoS Medicine</i> , 2016, 13, e1002078.	8.4	21
283	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. <i>Health Technology Assessment</i> , 2016, 20, 1-86.	2.8	12
284	Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 100.	6.8	206
285	Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the ADDITION-UK trial cohort. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000075.	2.8	8
286	Promotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 289.	1.6	22
287	Associations of mutually exclusive categories of physical activity and sedentary time with markers of cardiometabolic health in English adults: a cross-sectional analysis of the Health Survey for England. <i>BMC Public Health</i> , 2015, 16, 25.	2.9	81
288	Associations of Sedentary Time with Fat Distribution in a High-Risk Population. <i>Medicine and Science in Sports and Exercise</i> , 2015, 47, 1727-1734.	0.4	30

#	ARTICLE	IF	CITATIONS
289	Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE, 2015, 10, e0126427.	2.5	161
290	The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS ONE, 2015, 10, e0126769.	2.5	127
291	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 2015, 19, 1-80.	2.8	24
292	Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care, 2015, 38, 1449-1455.	8.6	214
293	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 2015, 107, 320-331.	2.8	112
294	Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review. Clinical Medicine Insights: Endocrinology and Diabetes, 2015, 8, CMED.S20906.	1.9	45
295	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clinical Endocrinology, 2015, 83, 542-549.	2.4	32
296	Using an interactive DVD about type 2 diabetes and insulin therapy in a UK South Asian community and in patient education and healthcare provider training. Patient Education and Counseling, 2015, 98, 1123-1130.	2.2	11
297	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 2015, 38, 316-322.	8.6	276
298	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2015, 17, 194-202.	4.4	15
299	A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes). PLoS ONE, 2015, 10, e0143398.	2.5	56
300	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice, 2014, 64, e208-e216.	1.4	11
301	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2015-2023.	8.6	56
302	Adverse Responses and Physical Activity. Medicine and Science in Sports and Exercise, 2014, 46, 1617-1623.	0.4	12
303	Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411-3417. Diabetes Care, 2014, 37, e114-e114.	8.6	1
304	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Primary Care Diabetes, 2014, 8, 57-63.	1.8	12
305	Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Research and Clinical Practice, 2014, 104, 281-287.	2.8	45
306	Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations. Diabetes Care, 2014, 37, 922-933.	8.6	448

#	ARTICLE	IF	CITATIONS
307	Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes. <i>Primary Care Diabetes</i> , 2014, 8, 119-125.	1.8	1
308	Evaluation of the Clinical and Cost Effectiveness of Intermediate Care Clinics for Diabetes (ICCD): A Multicentre Cluster Randomised Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e93964.	2.5	21
309	Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 90.	2.4	142
310	Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. <i>Diabetologia</i> , 2013, 56, 2367-2377.	6.3	18
311	Clinical Inertia in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3411-3417.	8.6	508
312	Diabetes advice for women with polycystic ovary syndrome: prevention, prevention, prevention. <i>Diabetes Management</i> , 2013, 3, 467-480.	0.5	3
313	Screening, evaluation and management of depression in people with diabetes in primary care. <i>Primary Care Diabetes</i> , 2013, 7, 1-10.	1.8	91
314	The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose. <i>Primary Care Diabetes</i> , 2013, 7, 11-18.	1.8	14
315	Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. <i>Clinical Endocrinology</i> , 2013, 78, 926-934.	2.4	156
316	Quality of Care of People With Type 2 Diabetes in Eight European Countries. <i>Diabetes Care</i> , 2013, 36, 2628-2638.	8.6	215
317	Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?. <i>Diabetes Management</i> , 2013, 3, 367-378.	0.5	5
318	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. <i>PLoS ONE</i> , 2013, 8, e55580.	2.5	26
319	Sedentary Time and Markers of Chronic Low-Grade Inflammation in a High Risk Population. <i>PLoS ONE</i> , 2013, 8, e78350.	2.5	148
320	Association of Sedentary Behaviour with Metabolic Syndrome: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e34916.	2.5	388
321	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. <i>BMJ</i> , The, 2012, 344, e2333-e2333.	6.0	268
322	Standing up to diabetes: sedentary behavior matters. <i>Diabetes Management</i> , 2012, 2, 261-263.	0.5	0
323	Self-Reported Sitting Time and Markers of Inflammation, Insulin Resistance, and Adiposity. <i>American Journal of Preventive Medicine</i> , 2012, 42, 1-7.	3.0	116
324	A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 505-513.	2.8	60

#	ARTICLE	IF	CITATIONS
325	Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes. BMC Family Practice, 2012, 13, 46.	2.9	48
326	Letâ€™s prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology, 2012, 11, 56.	6.8	33
327	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. Trials, 2012, 13, 164.	1.6	8
328	Association of Sitting Time and Physical Activity With CKD: A Cross-sectional Study in Family Practices. American Journal of Kidney Diseases, 2012, 60, 583-590.	1.9	48
329	Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ, The, 2012, 345, e4624-e4624.	6.0	87
330	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, The, 2011, 378, 156-167.	13.7	406
331	Feasibility of a structured group education session to improve self-management of blood pressure in people with chronic kidney disease: an open randomised pilot trial. BMJ Open, 2011, 1, e000381-e000381.	1.9	13
332	Rationale and study design for a randomised controlled trial to reduce sedentary time in adults at risk of type 2 diabetes mellitus: project stand (Sedentary Time ANd diabetes). BMC Public Health, 2011, 11, 908.	2.9	39
333	The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data. Trials, 2011, 12, 107.	1.6	10
334	Diabetes prevention: A call to action. Indian Journal of Medical Research, 2011, 134, 579.	1.0	8
335	The association between depression and healthâ€™related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research and Reviews, 2010, 26, 75-89.	4.0	138
336	Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ: British Medical Journal, 2010, 341, c4229-c4229.	2.3	584
337	The European EUCCLID pilot study on care and complications in an unselected sample of people with type 2 diabetes in primary care. Primary Care Diabetes, 2010, 4, 17-23.	1.8	12
338	Has pay for performance improved the management of diabetes in the United Kingdom?. Primary Care Diabetes, 2010, 4, 73-78.	1.8	31
339	Clinical inertia in management of T2DM. Primary Care Diabetes, 2010, 4, 203-207.	1.8	79
340	Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance. Diabetes Care, 2009, 32, 1404-1410.	8.6	169
341	Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ: British Medical Journal, 2009, 339, b4731-b4731.	2.3	374
342	Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: A randomized controlled trial. Patient Education and Counseling, 2008, 73, 264-271.	2.2	44

#	ARTICLE	IF	CITATIONS
343	Educational Interventions in Kidney Disease Care: A Systematic Review of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2008, 51, 933-951.	1.9	116
344	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. <i>BMJ: British Medical Journal</i> , 2008, 336, 1180-1185.	2.3	239
345	Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2007, 334, 299.	2.3	930
346	Prevention of diabetes: A reality in primary care?. <i>Primary Care Diabetes</i> , 2007, 1, 119-121.	1.8	11
347	Ethnic Disparities in Diabetes Management and Pay-for-Performance in the UK: The Wandsworth Prospective Diabetes Study. <i>PLoS Medicine</i> , 2007, 4, e191.	8.4	117
348	Ethnicity and Quality of Diabetes Care in a Health System with Universal Coverage: Population-Based Cross-sectional Survey in Primary Care. <i>Journal of General Internal Medicine</i> , 2007, 22, 1317-1320.	2.6	46
349	Diabetes education and self-management for ongoing and newly diagnosed (DESMOND): Process modelling of pilot study. <i>Patient Education and Counseling</i> , 2006, 64, 369-377.	2.2	122
350	Empowering patients with diabetes: a qualitative primary care study focusing on South Asians in Leicester, UK. <i>Family Practice</i> , 2005, 22, 647-652.	1.9	84
351	Framework to aid analysis and interpretation of ongoing COVID-19 research. <i>Wellcome Open Research</i> , 0, 5, 208.	1.8	10